Title: Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Authors: Dimopoulos, M A ×
Palumbo, A
Attal, M
Beksaç, M
Davies, F E
Delforge, Michel
Einsele, H
Hajek, R
Harousseau, J-L
da Costa, F Leal
Ludwig, H
Mellqvist, U-H
Morgan, G J
San-Miguel, J F
Zweegman, S
Sonneveld, P #
Issue Date: May-2011
Publisher: Nature Publishing Group
Series Title: Leukemia vol:25 issue:5 pages:749-760
Abstract: An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma.Leukemia advance online publication, 4 February 2011; doi:10.1038/leu.2011.3.
ISSN: 0887-6924
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science